ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

JAZZ Jazz Pharmaceuticals PLC

120.51
0.00 (0.00%)
Pre Market
Last Updated: 07:35:11
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 120.00
Ask Price 125.49
News -
Day High

Low
111.2506

52 Week Range

High
147.98

Day Low
Company Name Stock Ticker Symbol Market Type
Jazz Pharmaceuticals PLC JAZZ NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 120.51 07:35:11
Open Price Low Price High Price Close Price Prev Close
120.51
Trades Volume Avg Volume 52 Week Range
0 0 - 111.2506 - 147.98
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 120.51 USD

Jazz Pharmaceuticals PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
7.51B 62.35M - 3.83B 414.83M 6.65 18.11
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Jazz Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No JAZZ Message Board. Create One! See More Posts on JAZZ Message Board See More Message Board Posts

Historical JAZZ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week125.31125.95117.71120.31826,707-4.80-3.83%
1 Month125.50125.95115.45119.66846,194-4.99-3.98%
3 Months125.82134.17113.55121.82633,982-5.31-4.22%
6 Months131.34137.385111.2506123.60675,627-10.83-8.25%
1 Year143.06147.98111.2506127.76590,865-22.55-15.76%
3 Years167.64189.00111.2506142.68591,603-47.13-28.11%
5 Years137.34189.0086.88139.39593,105-16.83-12.25%

Jazz Pharmaceuticals Description

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Your Recent History

Delayed Upgrade Clock